A new analysis has found that among patients with chronic lymphocytic leukemia, African Americans more commonly present with advanced disease, and they tend to have shorter survival times than Caucasians despite receiving the same care. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results suggest that biological factors may account for some racial disparities in cancer survival.
Among cancer patients, minorities tend to have a worse prognosis than Caucasians for reasons that are unclear. In African American patients, lower socioeconomic status and limited access to high-quality care often can play a role, but some researchers propose that certain cancers can behave more aggressively in minority individuals, which also can lead to worse outcomes.
Because chronic lymphocytic leukemia (CLL), a type of blood cancer, is rare in African Americans, investigators from The University of Texas MD Anderson Cancer Center in Houston and the Duke University Medical Center in Durham led a study that combined the two centers’ experiences with African American and Caucasian patients. Their analysis included 84 African American patients and 1,571 non-black patients referred to the two centers. All patients, regardless of race, had access to healthcare services and received the same treatments. “We sought to isolate race as a prognostic factor from other known demographic and clinical prognostic parameters in CLL,” explained Dr. Falchi.
The investigators found that while the time from diagnosis (made either incidentally or because of clinical symptoms) to referral was shorter for African Americans than Caucasian patients, African Americans were more likely to have CLL that was more advanced at the time of referral. Also, although African Americans responded as well to first-line therapy as Caucasian patients, their cancer progressed more rapidly and their survival was shorter. The inferior survival of African American patients persisted when patients were grouped according to factors related to the severity of their disease.
Anyone can get a blood cancer at any age. Around 30,000 people, from babies to grandparents, are diagnosed with blood cancer every year in the UK.
Of the 7,600 cases of leukaemia diagnosed in the UK every year, 94% are adults.
We are leading research into tailoring treatments so that rather than a one size fits all approach, every patient in the future will receive the individual treatment they need.
Childhood leukaemia is the most common form of cancer in children.
In 1960 when Leukaemia & Lymphoma Research was founded, a child diagnosed with leukaemia had almost no hope of survival.
Today 9 out of 10 children survive the most common form of leukaemia thanks to our continued investment in research into better treatments.
Around 11,700 people in the UK are diagnosed with lymphoma every year. Lymphoma is challenging to treat mainly because there are so many different types (over 35) of this blood cancer.
Lymphoma is the most common blood cancer in young people aged 15 to 24.
Thanks to our pioneering research, doctors are able to diagnose lymphoma more accurately which means every lymphoma patient receives the best possible care.
“These findings suggest that while inducing similarly high response rates, standard treatments do not overcome racial differences in outcome among patients with CLL,” said Dr. Ferrajoli. She added that a number of questions remain unanswered. For example, do distinct biologic characteristics of African American patients with CLL account for the disparities seen in this study? And will these findings hold in the general population, where the impact of socioeconomic status may be more varied?
In an accompanying editorial, Christopher Flowers, MD, of Emory University in Atlanta, and Barbara Pro, MD, of Thomas Jefferson University in Philadelphia, noted that to adequately study disparities in leukemia, investigators will need to collect specimens and clinical data from patients to examine the potential impact of molecular and biologic markers. “Future studies in CLL can use this work as a cornerstone for investigating racial disparities in this disease,” they wrote.
Hematologic cancers, (cancers of the blood, bone marrow, and lymph nodes) include leukemia, lymphoma, and myeloma.
Approximately every 4 minutes one person in the United States is diagnosed with a blood cancer.
More than 148,000 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2012.
New cases of leukemia, lymphoma and myeloma are expected to account for 9.0 percent of the estimated 1,596,670 new cancer cases diagnosed in the US in 2011.